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Introduction: YH4808 is a highly potent, selective and 
reversible potassium-competitive acid blocker of the H+/K+-
ATPase under clinical development to treat gastric acid-related 
diseases. The pharmacokinetics of YH4808 was dose-
proportional in humans after a single oral dose at 30-800 mg. 
However, the systemic exposure to YH4808 decreased after 
multiple oral administrations, particularly at higher doses (200 
and 400 mg). The reduced solubility of YH4808 caused by 
ii 
elevated intragastric pH after treatment with YH4808 was 
suggested as the main cause of the reduced exposure. In this 
study, first, a physiologically-based pharmacokinetic (PBPK) 
model was developed to predict the pharmacokinetic (PK) 
profiles of YH4808 after single and multiple administration and 
investigate the mechanistic basis of the decreased exposure of 
YH4808 after repeated oral administration at higher doses 
using the developed human PBPK model. Second, we developed 
a pharmacokinetic and pharmacodynamics (PK/PD) model to 
quantitatively evaluated the mutual relationships between the 
plasma concentrations of YH4808 and the time course of 
intragastric pH after single and multiple oral administration in 
humans. 
 
Methods: A PBPK model was developed using the 
physicochemical data, in vitro preclinical and clinical data of 
YH4808, which was further refined using human plasma 
concentrations obtained from a single-dose ascending phase I 
clinical trial of YH4808 with the SimCYP (Certara USA, Inc., 
Princeton, USA). Compartments were included for the brain, 
heart, lung, kidney, muscle, spleen, liver, gastrointestinal (GI) 
tract, pancreas, and a combined compartment for the remaining 
iii 
tissues. All compartments except the GI tract and liver were 
assumed to be well-stirred and their clearances were limited 
by blood flow. The absorption of YH4808 was described by the 
advanced dissolution, absorption and metabolism (ADAM) 
model implemented in SimCYP® , which divides the GI tract into 
nine segments, assuming permeability-limited disposition in the 
GI tract and liver. Biliary route is the major elimination pathway 
of YH4808, and the clearance was estimated using in vitro 
hepatic microsomal intrinsic clearance data. 
A PK/PD model was developed simultaneously using pooled 
data of the plasma concentrations of YH4808 and intragastric 
pH profiles obtained from healthy subjects who received a 
single (30-800 mg) or multiple (100-400 mg) oral doses or 
their matching placebos (intragastric pH only). The modeling 
was conducted using the first-order conditional estimation with 
interaction (FOCE-I) method implemented in NONMEM version 
7.3 (ICON Development Solutions, Ellicott City, MD, USA). The 
effects of covariates (i.e., age, body weight and height) were 
also evaluated and tested. The final model was qualified based 
on the precision of parameter estimates, diagnostic plots and 
visual predictive check plots. 
 
iv 
Results: In PBPK modeling study, the PK profiles of YH4808 in 
human after multiple oral administrations (100, 200 and 400 mg) 
were predicted using a refined PBPK model, and the PBPK 
model adequately predicted the observed concentrations at 100 
mg dosing. However, the model failed to predict a decreased 
exposure after multiple oral administrations at higher doses of 
200 and 400 mg. The reduced solubility of YH4808 at higher 
pH was hypothesized as the main cause of the reduction in 
exposure such that absorption was decrease as pH was 
increased. It was confirmed by PBPK modeling and simulation, 
where intragastric pH was increased by YH4808.  
In PK/PD modeling study, a two-compartment PK model with 
lagged first-order absorption model and a sigmoid maximum 
effect model linked with an effect compartment best described 
the observed YH4808 plasma concentrations and intragastric 
pH profiles over 24-hour period after YH4808 dosing, 
respectively. To address changes in intragastric pH over time 
affecting the plasma concentration of YH4808, we introduced a 
feedback path such that increased intragastric pH decreases the 




Conclusion: A PBPK model adequately predicted observed 
concentrations of YH4808 after single and multiple 
administration in human, and a simulation experiment based on 
the human PBPK model indicated that the pH-dependent 
solubility of YH4808 could have resulted in the reduced 
exposure after multiple administration. A PK/PD model also 
adequately described quantitatively mutual relationships 
between the plasma concentrations of YH4808 and the time 
course of intragastric pH after single and multiple 
administration in humans. Our analysis provides mechanistic 
insight into relationship between the exposure to YH4808 and 
intragastric pH, which allow for devising optimal dosing 
regimens for YH4808.  
 
* A part of this work is published in the European Journal of 
Pharmaceutical Sciences (Lee HA, Lee KR, Jang SB, Chung SY, 
Yu KS, Lee H. A physiologically-based pharmacokinetic model 
adequately predicted the human pharmacokinetic profiles of 
YH4808, a novel K+-competitive acid blocker. Eur J Pharm Sci. 
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The potassium-competitive acid blocker (P-CAB) and proton 
pump inhibitors (PPIs) are potent acid-reducing agents (ARAs) 
to treat patients with gastroesophageal reflux disease, peptic 
ulcer disease, and other acid-related diseases. P-CABs inhibit 
the activity of the gastric H+/K+-ATPase by reversible K+-
competitive ionic binding to the enzyme, leading to reduced H+ 
transport into the parietal cell canaliculus in exchange for K+ 
[1,2]. Unlike PPIs such as omeprazole, rabeprazole, and 
lansoprazole, P-CABs do not require prior proton pump 
activation to achieve antisecretory effect [3]. Furthermore, the 
inhibition of acid secretion by the P-CAB is fast because it 
rapidly reaches the peak plasma concentration after oral 
administration [4]. For example, BY841, a P-CAB, reached the 
peak serum concentrations 0.5-1.5 hours post-dose [5]. 
Likewise, revaprazan,(i.e.,YH1885) another P-CAB, achieved 
the peak plasma concentrations within 1.3-2.5 hours after a 
single oral dose [6]. Additionally, the clinical utility of PPIs has 
been limited due to their large inter-subject variability, partly 
attributed to the genetic polymorphisms in the cytochrome 
P450 (CYP) isozymes, particularly CYP2C19, that metabolize 
2 
PPIs in the liver (except for tenatoprazole)[7]. Because of the 
sensitivity of PPIs to CYP2C19, the pharmacokinetic (PK) 
profiles of PPIs could vary largely between extensive, 
intermediate, and poor metabolizers [8]. Therefore, P-CABs 
may offer additional therapeutic advantages including a faster 
onset of action and greater and prolonged efficacy over the 
entire dosing interval than PPIs [9].  
YH4808(2-(1-Allyl-2,3-dimethyl-1H-pyrrolo[2,3-
c]pyridine-7-yl)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride) is a novel, selective and reversible P-CAB 
under clinical development to treat gastroesophageal reflux 
disease and peptic ulcer disease (Yuhan Corporation, South 
Korea)[10]. YH4808 is a highly potent and selective H+, K+-
ATPase inhibitor compared with other reference compounds 
including esomeprazole [10]. Because YH4808 is rapidly 
absorbed and does not require an acidic environment for 
activation or protonation, YH4808 can immediately bind to the 
H+/K+-ATPase inhibitor, which leads to fast and marked 
inhibition of gastric acid secretion compared with esomeprazole, 
a PPI. To support this notion, the half maximal inhibitory 
concentration (IC50) of YH4808 for H
+/K+-ATPase was almost 
1,000 times lower than that of esomeprazole (3.4 vs. 3365 
3 
nM).11 YH4808 is extensively distributed in the gastric tissue 
after oral administration [11]. In addition, YH4808 is 
metabolized by various CYP isozymes, which makes the PK and 
pharmacodynamics (PD) of YH4808 less dependent on 
CYP2C19, which is genetically polymorphic [10]. M3 and M8 
were identified as the major metabolites of YH4808 in vitro and 
in vivo across the various species including humans although 
the major pharmacologic activity appeared to arise from the 
parent drug [10]. YH4808 did not significantly inhibit or induce 
CYP450 isozymes including CYP1A2, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6 and 3A4 in human hepatic microsomes, suggesting 
little potential for drug-drug interactions (DDIs) (in-house 
data). In a previous clinical study, after YH4808 100-400 mg 
had been administered for 7 days, YH4808 maintained 
intragastric pH >4 for approximately 70% of a 24-hours time 
period. Although YH4808 exhibited a dose-proportional PK 
profiles at a single dose of 30-800 mg, the systemic exposure 
of YH4808 decreased after multiple oral administrations, 
particularly at higher doses (200 and 400 mg) [10]. The 
reduced solubility of YH4808 by elevated pH after multiple 
administrations was hypothesized as the main cause of the 
reduction in exposure.  
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Modeling and simulation have the potential to be 
important tools in all phases of new drug development from 
preclinical to clinical and post-marketing phases, providing 
scientific evidence upon which to base crucial decisions during 
all stages of a drug product’s life cycle. Modeling and simulation 
use of mathematical and statistical models that are essentially 
simplified descriptions of complex systems under investigation. 
One approach to such models is a “bottom-up” or 
physiologically-based pharmacokinetic (PBPK) approach, with 
models comprising equations and parameters that try to more 
closely reproduce underlying anatomic distributions and 
physiologic functions [12].  Recently, recognition of the value 
of PBPK modeling and simulation in predicting human PK was 
growing, especially regarding DDI risk. PBPK modeling analysis 
can simulate the PK profiles of a compound not only in the 
plasma, but also in other organs and tissues by integrating 
drug-specific (i.e., the absorption, distribution, metabolism, and 
excretion (ADME) and physicochemical properties of a 
compound) and system-specific information (e.g., human 
physiology, demographics, and heterogeneity)[13-15]. This 
PBPK modeling analysis (i.e., “bottom-up ”  approach) has 
been recently used in the clinical development to evaluate how 
5 
food, formulation and acid reducing agents (ARAs) impact drug 
absorption [16,17]. Furthermore, when combined with PD 
models, a PBPK model can be also used to estimate the time 
course of drug response [15].    
The alternative is the “top-down” system of empirical 
equations with relatively few parameters. Equations and 
estimation of the probability distribution of parameters are not 
chosen to faithfully reproduce underlying anatomy and 
physiology but to best reproduce the distribution of observed 
data. Model validation is based on bias, imprecision, and 
distribution of predictions relative to the original or to external, 
independent data. This is most often termed “population 
pharmacokinetic/pharmacodynamics (PK/PD) modeling” 
[18,19]. Population PK/PD modeling based on clinical PK and 
PD observation characterizes the impact of intrinsic and 
extrinsic factors (covariates) on the inter-individual variability 
(IIV) in PK parameters using compartmental and increasingly 
mechanistic models. Population PK/PD modeling also uses to 
link PK and PD in order to establish and evaluate dose-
concentration-response relationships and subsequently 
describes and predicts the effect-time courses resulting from a 
drug dose [20]. In clinical drug development, PK/PD modeling 
6 
using data of phase I dose escalation studies on healthy 
subjects provides information for the rationale design of all 
subsequent clinical development phases, especially in 
identifying effective and safe dosage regimens before large 
clinical trials are started.  
Especially, mechanism-based population PK/PD model 
quantitatively characterize specific processes on the causal 
path between drug administration and effect. Most mechanism-
based population PK/PD models typically integrate PK (e.g., 
PBPK) reflecting the relevance physiology and disease, and the 
nature of drug-target interaction (i.e., pharmacology) (Figure 
1).  Mechanism-based PK/PD model constitutes a scientific 








Figure 1. Major components contributing to assembly of 
mechanism-based pharmacokinetic/pharmacodynamic models 
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In the case of capecitabine, orally administered triple 
pro-drug of 5-fluorouracil that is approved for the treatment 
of breast and colorectal cancer, a mechanism-based PK/PD 
modeling combined with PBPK modeling approach used in a 
development to provide a more thorough understanding of what 
the key predictors of its PBPK activity are, and how variability 
in these predictors may affect its PK and PD, and ultimately, 
clinical outcomes [21]. The mechanism-based PK/PD model 
combined with PBPK modeling using clinical data were 
developed to characterize the activity of capecitabine and its 
metabolites, and the clinical outcomes under varying 
physiological conditions such as creatinine clearance or activity 
of key metabolic enzymes. The results of these modeling were 
consistent with capecitabine’s rational design. In our study, we 
developed both PBPK and mechanism-based PK/PD model to 
confirm and evaluate the relationships between the plasma 
concentrations of YH4808 and the time course of intragastric 
pH after single and multiple oral administrations in humans.  
First, we developed the PBPK model to investigate why the 
systemic exposure decreases after multiple oral administration, 
and then the mechanism that explain the decrease exposure 
was applied to the PK/PD model. In other words, this study 
8 
provides a real-life case in clinical drug development, where 
both PK/PD ( “ top-down ” ) and PBPK ( “ bottom-up ” ) 
approaches are applied using all the available data (in vitro, 
nonclinical and clinical (healthy volunteers)) to elucidate how 




The main objectives of this study are 1) to develop a human 
PBPK model of YH4808 using its physicochemical properties 
and in vitro and in vivo pre-clinical data to predict the PK 
profiles of YH4808 in various clinical settings after single and 
multiple oral administrations for further clinical development, 2) 
to investigate the mechanistic basis of the decrease exposure 
to YH4808 after repeated oral administration at higher doses 
using the developed human PBPK model, and 3) to develop a 
mechanism-based PK/PD model to quantitatively evaluate the 
mutual relationships between the plasma concentrations of 
YH4808 and the time course of intragastric pH after single and 






1. Physiologically-based pharmacokinetic (PBPK) 
modeling of YH4808 
1.1 Materials 
YH4808 (Figure 2) was synthesized at Yuhan Corporation, 
Seoul, South Korea. Oxybutynin (internal standard) was 
supplied by Sigma-Aldrich (St.Louis, MO, USA). Pooled human, 
rat and mouse microsomes were purchased from BD Gentest 
(Woburn, MA, USA), and dog and monkey microsomes were 
purchased from In vitro Technologies, Inc. (Melbourne, 
Australia). All the other reagents (acetonitrile, methanol, formic 
acid, and ammonium formate) were commercial products of 






Figure 2. Chemical structure of YH4808 
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1.2. Caco-2 transcellular permeability 
Human colon adenocarcinoma cells (Caco-2) were obtained 
from Korean Cell Line Bank (Seoul, South Korea). The cells 
were cultured for 21 days in 12 transwell under 95% air/5% 
CO2, relative humidity of 90% and 37C. On the experiment day, 
the integrity of the cell monolayer was evaluated by measuring 
the transepithelial electrical resistance (TEER) using a EVOM 
Epithelial Volt/ohm-meter (World Precision Instruments, FL, 
USA). The incubation medium was Hank ’ s balanced salt 
solution containing 25 mM N-2-hydroxyethylpiperazine-N’-
2-ethanesulfonic acid and 25 mM glucose at pH 7.4. The test 
compound solution was prepared by diluting 0.5% dimethyl 
sulfoxide (DMSO) stock solution (all tested at a final 
concentration of 0.1-10 μM). Incubations were started by 
placing the test compound at the apical side of the transwell for 
assessing the permeability in the A to B (apical to basolateral) 
direction and the incubation lasted 80 minutes in a 37C 
incubator. Mannitol was used as the quality control of the given 
batch of the Caco-2 culture.  
The apparent permeability coefficient (Papp) values were 
calculated as follows: 
11 






             (1) 
,where A, C0 and dQ/dt represent the insert surface area (cm
2), 
initial donor drug concentration (μM) and the amount of drug 
transported within a given time period (μmol/sec), respectively. 
 
1.3. Metabolic stability 
Pooled microsomes from rat, mouse, dog, monkey and human 
liver were used for assays. Incubations (400 μL) consisted of 
liver microsomes (1 mg/mL), NADPH generating system (0.1 
M glucose 6-phosphate, 1 unit glucose 6-phosphate 
dehydrogenase, 10 mg/mL β-NADPH+) and 0.1 M potassium 
phosphate buffer (pH 7.4). Following pre-incubation (5 min, 
37℃), reactions were initiated by spiking stock solutions of 
YH4808 (10 μM). Samples were taken at 0, 10, 20, 30, 45, 60, 
and 120 min and quenched with methanol. Then, the samples 
were centrifuged for 10 min at 3,000 rpm, and the supernatants 
(5 μL) were analyzed by LC-MS/MS. The metabolic half-life 
(t1/2) was calculated based on the slope of the declining portion 
on the linear regression line for the natural logarithm-
transformed remaining percentage of the substrate versus 
incubation time. 
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1.4. Inhibition of CYP enzymes by YH4808 
The effect of YH4808 (0.1-50 μM) on the metabolism of 
substrates by corresponding selective CYP enzymes was 
investigated using pooled human liver microsomes (1 mg/mL). 
The following drugs were used as CYP substrates: 40 μM 
phenacetin (CYP1A2), 2.5 μM coumarin (CYP2A6), 10 μM 
paclitaxel (CYP2C8), 10 μM diclofenac (CYP2C9), 5 μM 
dextromethorphan (CYP2D6), and 2.5 μM midazolam 
(CYP3A)[22]. Individual substrates were pre-incubated with 
human liver microsomes in the presence of YH4808 for 5 min at 
37C before the addition of an NADPH-generating solution. A 
cocktail of 6 probe substrates was incubated for 15 min at 37C, 
and then the reactions were terminated by adding 40 μL of a 
stop solution consisting of acetonitrile and 10 μM 
chlorpropamide. In vitro high-throughput P450 cocktail 
inhibition assay was used 6 substrates simultaneously against 6 
CYP isozymes, and the samples were analyzed using an LC-
MS/MS system. Control incubations were performed using 
carrier vehicle only. The extent of enzyme inhibition was 
expressed as the percentage of remaining enzyme activity 
compared with the control (in the absence of inhibitor). The 
inhibition data were fit to an enzyme inhibition model using a 
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nonlinear least-squares regression analysis (WinNonlin 4.0, 
Pharsight, A Certara Company, Princeton, NJ, USA). IC50 were 
determined with each of the CYP substrates. Inhibition potential 
was classified into three categories: potent (IC50 < 1 μM), 
moderate (1 μM < IC50 < 10 μM), and no or weak inhibition 
(IC50 > 10 μM)[23]. 
 
1.5. Plasma protein binding 
The protein binding of YH4808 was determined in rat, dog, 
monkey and human plasma at two concentrations (150 and 300 
ng/mL). The protein binding ratio was determined using 
ultracentrifuge devices (OptimaTM LE-80K, SW 60 Ti, 
Beckman Coulter, Indianapolis, IN, USA). Pooled male Sprague 
Dawley rat plasma was obtained from Innovative Research, and 
pooled human male plasma was purchased from Biomedex Inc. 
(Spokane, WA, USA).  Pooled male beagle dog plasma and 
pooled male Cynomolgus monkey plasma were obtained from 
Yuhan Research Institute. YH4808, prepared in methanol as 
stock solution (1,000 μg/mL), was diluted in plasma to achieve 
the target concentrations. All measurements were performed in 
triplicate. Plasma samples were incubated for 30 min at 37C 
and ultracentrifuged at 406,484.7 g for 5 hours at 4C. After 
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finishing ultracentrifugation, 0.05 mL supernatant was mixed 
with 150 μL internal standard (oxybutynin, 500 ng/mL in 100% 
acetonitrile). The mixture was vortex-mixed for 30 secs and 
then centrifuged at 13,000 rpm for 10 min. The supernatant 
(100 μL) after centrifugation was transferred to HPLC auto-
sampler vials and 7 μL was injected into the LC-MS/MS 
system. 
The percentage of unbound drugs was calculated as follows: 
% unbound drugs =  
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 𝑑𝑟𝑢𝑔𝑠
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 𝑑𝑟𝑢𝑔𝑠 +𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠  
 × 100          
(2) 
 
1.6. Human pharmacokinetic study 
Clinical PK data of YH4808 after single and multiple oral 
administration was obtained in a previous study [10], which 
was performed using a randomized, double-blind, single and 
multiple ascending dose design in healthy male subjects, 20-45 
years of age, with a body weight >50 kg, and within ±20% of 
ideal body weight. The doses of YH4808 were 50, 100, 200 and 
400 mg in the single dose study, and 100, 200 and 400 mg once 
daily for 7 days in the multiple dose study. For the PK analysis, 
blood samples were collected pre-dose (0 hour), 0.25, 0.5, 
0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose, 
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on Day 1 and 7 (the multiple dose study only). The PK 
parameters were estimated using a non-compartmental method 
implemented in Phoenix 6.4 software (WinNonlin 6.4., Pharsight, 
A Certara Company, Princeton, NJ, USA).  
 
1.7. PBPK modeling in humans 
A human PBPK model was developed using the physicochemical 
data of YH4808 and human physiological data (Figure 3). The 
compound-specific physicochemical (i.e., molecular weight, 
Log P, pKa and pH-solubility profile) and in vitro (i.e., fraction 
unbound. Caco-2 permeability, metabolic stability and inhibition 
of CYP enzymes) of YH4808 were obtained from Investigator 
Brochure provided by Yuhan Corporation, Seoul, South Korea. 
The advanced dissolution, absorption, and metabolism (ADAM) 
module in the SimCYP®  Simulator was used to account for 
intestinal permeability in humans. We simulated the PK profiles 
of YH4808 in humans using the final animal PBPK model 
complemented by human in vitro data of YH4808 including 
microsomal clearance, plasma free fraction, and Caco-2 cell 
permeability along with YH4808-specific physicochemical data 
(Table 1). Each simulation was performed using 100 virtual 
males (i.e., 10 trials x 10 subjects), who had a mean body 
16 
weight of 70 kg with age ranging from 21 to 38 years as in the 
clinical study [10]. The dose, dosing interval, and dosing 
duration of YH4808 in the simulation were identical to those 









Figure 3. Schematic description of the physiologically-based 
pharmacokinetic model of YH4808 
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Species Human (50-90kg) 
Physicochemical 
property 




YH4808 for a 








Log P 1.2 
Compound type Monoprotic base 
pKa 6.995 
pH-solubility profile 
2.137 mg/mL at pH=2.0; 
0.046 mg/mL at pH=6.0 
Fraction unbound 0.0046 
Absorption 
Absorption type 
Advanced Dissolution, Absorption and 
Metabolism (ADAM) model 














































Km (µM) 13.0 






 Rodgers et al., (2005), J Pharm Sci 94(6):1259-1276, and Rodgers and Rowland (2006) J Pharm Sci 
95(6):1238-1257 
b
 Vmax: Maximum rate of metabolite formation (pmol/min/mg protein) 
c
 Km: Michaelis-Menten constant (µM) 
d





1.8. Model optimization 
We compared the PBPK model-predicted plasma 
concentration-time profiles of YH4808 with the observed ones 
in rats and dogs, which were further optimized by the 
Parameter Estimation module within the SimCYP®  Simulator. 
The Parameter Estimation module adjusts estimated 
parameters such that they could better predict observed 
concentrations. Primarily, a least square objective function was 
fitted using the Nelder-Mead algorithm (Nelder and Mead, 
1965). The expectation-maximization method was used to 
solve the maximum likelihood problem. Then, we further 
optimized the human PBPK model to adequately predict the 
concentration-time profiles of YH4808 in humans after a single 
oral administration at 50, 100, 200 and 400 mg. To this end, 
effective intestinal permeability (Peff) values were estimated by 
the Nelder-Mead algorithm of the Parameter Estimation module 
in the SimCYP®  Simulator. Finally, the optimized human PBPK 
model was used to predict the PK profiles of YH4808 after 




1.9. Model validation (drug-drug interactions, DDIs) 
To validate the human PBPK model for YH4808, we simulated 
DDIs using the developed human PBPK model. For simulations 
of DDIs, the total clearance of YH4808 was primarily defined by 
the metabolic clearance. The metabolic clearance was defined 
by enzyme kinetic parameters, the maximum rate of metabolite 
formation (Vmax) and the Michaelis-Menten constant (Km) 
values, determined from the formation rate of metabolite 
CYP2C19 and CYP2D6 recombinant system (Table 1). Vmax and 
Km values were determined by nonlinear fitting using GraphPad 
Prism (La Jolla, CA, USA).  The input inhibition constants (Ki) 
for CYP2C19 and CYP2D6 of YH4808 were obtained from 
experimental in vitro data (Table 1).  The human PBPK model 
was utilized to simulate changes in the PK profile (AUC) of 
YH4808, substrate, in the presence of a strong CYP2C19 and 
CYP2D6 inhibitor (fluvoxamine for CYP2C19, fluoxetine for 
CYP2D6). Compound files for fluvoxamine 50 mg once daily and 
fluoxetine 40 mg once daily were used as provided in the 
SimCYP®  Simulator.  The predictive performance of DDIs using 
the human PBPK model of YH4808 was determined by 
calculating the ratio of model predicted exposure changes in 
substrate (AUCratio) [27]. Predicted AUCratio was defined as 
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AUCwith inhibitor/AUCwithout inhibitor. The ratio of YH4808 AUC in the 
presence of an inhibitor (fluvoxamine and fluoxetine) to 
YH4808 AUC in the absence of an inhibitor was used as a 
measurement of magnitude of interaction.  
 
1.10. Evaluation of model performance 
We assessed the adequacy of the PBPK model first by visually 
comparing the model-predicted and observed concentration-
time profiles of YH4808. Then, a ratio of the model-predicted 
to observed mean values was calculated for the PK parameter 
of YH4808 such as the area under the plasma concentration-
time curve (AUC) from time 0 to the last observable 
concentration (AUC0-t), AUC from time 0 to infinity (AUCinf), 
AUC over dosing interval (AUCτ), the peak concentration 
(Cmax), and time to reach Cmax (Tmax). We concluded that the 
PBPK model performed adequately when a ratio of the model-




2. Mechanism-based pharmacokinetic and 
pharmacodynamics (PK/PD) modeling of 
YH4808 
 
2.1. Study design and subjects 
The plasma concentration and intragastric pH data of YH4808 
were derived from a phase I study conducted at the Clinical 
Trials Center in SNUH from 2009 to 2011.  
 
Study design 
This was a randomized, double-blind, placebo- and active 
comparator-controlled clinical study performed in two parts: a 
single ascending dose study (30, 50, 100, 200, 400, 600 and 
800 mg), and a multiple ascending dose study (100, 200 and 
400 mg once daily for 7 days). After an overnight fast, eligible 
subjects randomly received a single oral dose or multiple oral 
daily doses of YH4808 at the assigned dose, or placebo. 24-
hours continuous, ambulatory intragastric pH monitoring on Day 
-1 (baseline), and Day 1 in the single dose study; on Day -1, 
Day 1, and Day 7 in the YH4808 100 mg and the 400 mg groups 
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in the multiple dose study. The YH4808 200 mg group in the 
multiple dose study received intragastric pH monitoring only on 
Day -1 and Day 7. 
 
Subjects 
Healthy male subjects aged 20 - 45 years with a body weight 
of >50 kg and within ±20% of ideal body weight were enrolled 
in this study provided that they presented no abnormalities 
based on medical history, physical examination, 12-lead 
electrocardiogram, serology (HBsAg, anti-HCV and anti-HIV 
antibody), clinical laboratory tests (chemistry, haematology and 
urinalysis), and urine drug screening. In the single dose study, 
subjects who were both positive and negative for Helicobacter 
pylori (H. pylori) were enrolled to explore the effects of 
YH4808 on intragastric pH profiles in the presence and absence 
of H. pylori infections. However, in the multiple dose study, H. 
pylori-negative subjects were only enrolled to avoid the effect 
of H. pylori infections on intragastric pH. Written informed 
consent was obtained before any study-related procedure was 
performed. This study was approved by the Institutional 
Review Board at SNUH, Seoul, South Korea, and was conducted 
in accordance with the principles of the Declaration of Helsinki 
24 




Figure 4. Mean plasma concentration-time profiles of YH4808 
(left: linear scale; right: semi-log scale). Data presented as 
mean±standard deviation. 
30-800 mg single doses of YH4808 under fasted conditions 























Figure 5. Mean 24 hr intragastric pH vs. time profiles of 
YH4808. 
30-800 mg single doses of YH4808 (top); multiple dose of 






2.2. Population pharmacokinetic/pharmacodynamic model 
development 
The plasma concentrations of YH4808 and intragastric pH 
profiles obtained from healthy subjects who received a single 
(30-800 mg) or multiple (100-400 mg) oral doses or their 
matching placebos (intragastric pH only) were pooled for a 
PK/PD analysis. A population PK/PD analysis was 
simultaneously performed using the first-order conditional 
estimation (FOCE) with interaction method implemented in 
NONMEM®  version 7.3 (ICON Development Solutions, Ellicott 
City, MD, USA). For graphical visualization, RStudio (Version 
1.0.153, The R Foundation for Statistical Computing, Vienna, 
Austria) was used. Model selection was based on the difference 
in objective function value (OFV), the graphical analysis of 
goodness-of-fit plot, and the relative standard error reflecting 
the precision of the parameter estimates. 
 
Pharmacokinetic model development 
Following visual assessment of the concentration-time profiles 
of YH4808 in phase I study (Figure 4), a 2-compartment 
disposition model with first-order absorption was evaluated as 
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the structural PK model for this analysis.  To describe the 
rapid increase in plasma concentrations of YH4808, the model 
including lag time (ALAG1) was evaluate as well. The 
disposition kinetics were parameterized in terms of apparent 
clearance (CL, L/h), apparent volume of distribution (V2 for 
central, and V3 for peripheral volume, L), intercompartmental 
clearance (Q, L/h), and absorption rate constant (Ka, 1/h) using 
ADVAN13 and the first-order conditional estimation method 
with interaction (FOCE-I). The inter-individual variability (IIV) 
of the PK parameters was evaluated using an exponential error 
model, and the residual variability (RV) was evaluated using a 
combined proportional and additive random effects model. Age, 
body weight and height of subjects following baseline measures 
were included in the covariate screening. 
 
Individualized baseline model development for intragastric pH 
It is well known that intragastric acid secretion is circadian in 
nature, producing intragastric acid pH values that are higher at 
night and lower during the day [30] and individual gastric pH 
with typical food related circadian rhythm [31]. Therefore, a 
baseline model for this rhythm should be incorporated into the 
PD model to precisely estimate the drug effect.  
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 The gastric pH of YH4808 in the 24-h circadian rhythm 
study was modeled by harmonic functions, as follows:   
Gastric pH =
𝑎0 + 𝑎1 cos [
2𝜋(𝑇𝐴𝐷−𝑏1)
24
] + 𝑎2 sin [
2𝜋(𝑇𝐴𝐷−𝑏2)
18







]                                                     
(3) 
,where a0 is the mean gastric pH, ai is an amplitude, bi is a peak 
time, TAD represents the time elapsed after placebo 
administration, and 2π/24, 2π/18, 2π/12 and 2π/6 convert 
time to radians. 
 
Pharmacokinetic/pharmacodynamic model development 
An effect compartment model, which assumes the rate of drug 
distribution to and from the hypothetical effect site will 
determine the rate of onset of effect, was implemented to relate 
plasma concentrations of YH4808 to the change of intragastric 
pH because the increase of intragastric pH in each subject 
lagged behind the plasma concentration time course of YH4808. 
In such a model, the time course of the effect site concentration 
(Ce) is described by the rate constant (ke0) from the effect 
compartment.  
29 
 A sigmoid maximum effect (Emax) model with a baseline 
effect was tried to fit the intragastric pH data, and it was 
simultaneously applied to predict the plasma concentration of 
YH4808 following single and multiple oral administration. 
                             Gastric pH =  𝐸0  × (1 +  
𝐸𝑚𝑎𝑥 × 𝐶𝐸
𝐸𝐶50+𝐶𝐸
)            (4) 
,where E0 is the placebo effect (baseline), Emax is the maximum 
effect of intragastric pH, EC50 is the drug concentration that 
produces 50% of the maximal effect, and CE is the 
corresponding effect compartment concentration. The IIV of the 
PD parameters was evaluated using an exponential error model, 
and the additive error model was used to present the RV of the 
drug effect.  
 
Model evaluation 
A visual predictive check (VPC) was performed for the 
evaluation of the final population PK and PK/PD models. Using 
the final model, 1000 simulated replicates of the original dataset 
were generated, and the median and the 5th and 95th percentiles 
calculated from simulated concentrations were compared with 
the measured concentrations. Additionally, to validate the 
reliability and stability of the model, a non-parametric 
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bootstrap analysis was performed. The final PK and PD 
parameters were compared with 95% confidence intervals (CIs) 
calculated using the 2.5 and 97.5 percentiles obtained from 




1. Physiologically-based pharmacokinetic (PBPK) 
modeling of  YH4808 
1.1. Caco-2 transcellular permeability 
The average apparent permeability (Papp) for YH4808 (i.e., 
apical to basolateral direction) was 1.49 x 10-5 cm/sec over the 
drug concentration range of 0.1-10 μM. There was no 
evidence of flux saturation with increased drug concentration. 
YH4808 is highly permeable, i.e., Papp >5.0 x 10
-6 cm/sec, 
indicating the compound is expected to be well absorbed 
through the gastrointestinal epithelial membrane [32]. 
 
1.2. Metabolic stability 
The remaining percentage of parent after 30 min was 39.8 
(human), 46.4 (rat), 2.6 (mouse), 21.7 (dog) and 6.1 % 
(monkey), and the values of the half-life (t1/2) in human, rat, 
mouse, dog and monkey liver microsomes were 17.7, 28.5, 5.3, 
7.5 and 3.2 min for YH4808 concentrations of 10 μM. The 
rapid decrease in the metabolic stability of YH4808 indicated 
that various metabolic pathways, mostly CYP isozymes, were 
32 
involved in the metabolism of YH4808. 
 
1.3. Inhibition of CYP enzymes by YH4808 
The IC50 values of CYP3A4, CYP2C9, CYP2C19, CYP2C8, 
CYP2A6 and CYP1A2 were 19.7, 23.9, 5.0, >25, >25 and 6.4 μ
M, respectively. YH4808 showed no apparent inhibition of these 
CYP P450 isozymes, thus, the result suggested little potential 
for DDIs of YH4808. 
 
1.4. Plasma protein binding 
The in vitro plasma protein binding rate of YH4808 was 99.17% 
(rats, 95% CI: 99.15-99.18%), 99.62% (dogs, 95% CI: 99.61-
99.63%), 98.45% (monkeys, 95% CI: 98.40-98.47%) and 
99.54% (humans, 95% CI: 99.52-99.54%), respectively.  
 
1.5. PBPK modeling and simulation in humans: single oral 
administration 
Physicochemical properties, combined with in vitro human data 
(clearance, permeability and plasma protein binding) and human 
physiological data were used to simulate human plasma 
concentration versus time profiles of YH4808 over a dose 
33 
range of 50-400 mg. The ratios of the human PBPK model-
predicted to observed mean values of PK parameters such as 
Cmax and AUC0-t were not within the predefined range (0.5-2 
fold). Therefore, the human PBPK model of YH4808 was 
further optimized using the Parameter Estimation module and 
plasma concentrations after a single administration in healthy 
volunteers at 50-400 mg. The optimized human PBPK model 
adequately simulated the observed plasma concentration-time 
profiles of YH4808 after a single oral administration over a 
dose range of 50 to 400 mg, particularly after optimization of 
intrinsic hepatic clearance and regional permeability in ADAM 
model (Figure 6). Furthermore, the ratios of the PBPK model-
predicted to observed mean values of PK parameters such as 
Cmax, Tmax and AUC0-t were all within the predefined range 









































Figure 6. Observed (different symbols for different subjects) 
and model-predicted (━) mean plasma concentration-time 
profiles of YH4808 in humans after single oral administration 
before (a, b, c, and d) and after (e, f, g, and h) optimization. 
The dashed lines represent the 5th and 95th percentiles of 
model-predicted plasma concentrations. 
Before Optimization After Optimization 
50 mg
Time (h)
































































































































































































































































































Table 2. Comparison of the model-predicted and observed pharmacokinetic parameters for YH4808 
after single oral administration in humans 
Cmax: Peak plasma concentration (ng/mL) 
Tmax: Time to reach Cmax following drug administration (hr) 
AUC0-t; Area under the plasma concentration-time curve from time 0 to the time of last observable concentration (ng∙hr/mL) 
Fold difference: The ratio of model-predicted to observed values 
Values are presented as arithmetic mean±SD, however, Tmax values represented as median (minimum, maximum).  



























PBPK 101.9 0.7 165.3 67.9 0.5 103.3 









 PBPK 173.2 0.7 261.2 186.9 0.5 262.2 









 PBPK 308.4 0.5 419.2 338.6 0.5 420.4 









 PBPK 582.7 0.5 714.1 627.1 0.5 703.3 
Fold difference 1.3 0.7 0.7 1.4 0.5 0.7 
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1.6. PBPK modeling and simulation in humans: repeated oral 
administration 
The simulated plasma concentration-time profiles of YH4808 
after repeated oral administration at 100, 200 and 400 mg were 
in line with the observed ones (Figure 7). Likewise, the ratio of 
the model-predicted PK parameter to the observed value fell 
entirely within the pre-specified range of 0.5-2.0 (Table 3). 
However, the PBPK model failed to predict the decrease in the 
systemic exposure to YH4808 after repeated administration, 
particularly at 200 and 400 mg. For example, the observed Cmax 
and AUC (AUCinf and AUCτ after a single and repeated oral 
administrations, respectively) of YH4808 at 400 mg were 
decreased by 56.3% and 46.3%, respectively, from Day 1 to 
Day 7 (Cmax: 480.7 vs. 210.3 ng/mL; AUC: 1149.9 vs. 618.0 ng∙
hr/mL, Table 3), whereas the model-predicted Cmax and AUC 
were almost the same between Days 1 and 7 (Cmax: 589.4 vs. 
592.5 ng/mL; AUC: 1322.5 vs. 1332.4 ng∙hr/mL, Table 3). 
     A power model analysis using logarithmically transformed 
Cmax and AUCτ versus logarithmically transformed dose 
showed that the systemic exposure to YH4808 increased in a 
less than dose-proportional manner in the range of 100-400 
37 
mg after repeated oral administration. The slope of the 
regression line was 0.26 (95% CI: -0.40-0.92) and 0.75 (95% 




















Figure 7. Observed (different symbols for different subjects) 
and model-predicted (━) mean plasma concentration-time 
profiles of YH4808 in humans after repeated oral administration 
at 100, 200 and 400 mg once a day. The dashed lines represent 
the 5th and 95th percentiles of model-predicted plasma 
concentrations. The observed plasma concentrations were 
obtained from subjects repeatedly administered with YH4808 at 
100, 200 and 400 mg in the multiple-ascending dose portion of 



































































































Table 3. Comparison of the model-predicted and observed pharmacokinetic parameters for YH4808 







Cmax: Peak plasma concentration (ng/mL) 
AUCinf:
 
Area under the plasma concentration-time curve from time 0 to infinity (ng∙hr/mL) 
AUCτ:
 
Area under the plasma concentration-time curve over dosing interval (ng∙hr/mL) 
Fold difference: The ratio of model-predicted to observed values 






1.7. Model validation (DDIs) 
Fluvoxamine (50 mg once daily), a strong CYP2C19 inhibitor, 
was predicted to increase the AUC of YH4808 only by a 1.5-
fold. Likewise, fluoxetine (40 mg once daily), a strong CYP2D6 
inhibitor, was predicted not to affect the AUC of YH4808 (1.0-
fold increase). These simulated DDI results, i.e., no significant 
interactions between YH4808 and a CYP2C19 and CYP2D6 
inhibitor, confirmed similar findings from the in vitro CYP 
inhibition study. 
 
1.8. PBPK simulation for the effect of varying gastric pH 
As the intragastric pH was increased from 1.5 to 7, the Cmax and 
AUC0-t of YH4808 after oral administration at 400 mg were 
reduced from 375.7 to 267.0 ng/mL for Cmax and from 692.0 to 


















Figure 8. Model-predicted mean plasma concentration-time 
profiles of YH4808 after a single oral administration at 400 mg 












2. Mechanism-based pharmacokinetic and 
pharmacodynamics (PK/PD) modeling of 
YH4808 
2.1. Dataset and baseline subject demographics 
A total of 123 subjects completed the clinical study (83 and 40 
for the single and multiple dose studies, respectively) after 
having been randomly assigned to one of the dose groups in the 
single or multiple dose studies. The mean age and weight of the 
subjects were 25.5 years (range 20-41 years), and 67.5 kg 
(range 53.5-87.2 kg), respectively. Among the 123 subjects, 
1627 plasma concentrations and 1846 intragastric pH points 
from 80 subjects (56 and 24 for the single and multiple dose 
studies, respectively) were pooled for PK/PD analysis.  
 
2.2. Population pharmacokinetic/pharmacodynamic analysis 
Pharmacokinetic model 
A two-compartment model with a first-order absorption 
combined with lag-time adequately described the 
concentration-time profiles in healthy subjects following oral 
administration of YH4808 (Figure 9). Inter-individual 
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variability was estimated for the following PK parameters: 
apparent clearance (CL/F), apparent volumes of distribution of 
the central and peripheral compartments (VC/F and VP/F, 
respectively), apparent inter-compartmental clearance (Q/F), 
first-order absorption rate constant (Ka) and lag-time of the 
first-order process (ALAG1). Inter-occasion variability was 
not estimated for all PK parameters. Only body weight as a 




























 The effect of covariate, body weight, on the PK 
parameter (CL/F) is expressed in the following equation: 
             
𝐶𝐿
𝐹





               (5) 
Therefore, in general, the body weight had a positive 
relationship with the clearance (CL/F) of YH4808 as expected, 
and the typical value of the clearance (CL/F) parameter of 
YH4808 would be greater in heavier subjects.  
 The general goodness-of-fit plots, VPC plots and the 
bootstrap-resampling of the final PK model showed good 
adequacy between the observed and the predicted YH4808 
concentrations in plasma without discernible systematic bias 
(Figure 10 and Figure 11). The final PK model parameters 
were adequately estimated with median and 95% CIs generated 
by the bootstrap-resampled simulated trials (Table 4). In 
conclusion, the final PK model was robust in describing the PK 
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Proportional residual variability 
(CV%) 
 43.1  
Additive residual variability ng/mL 0.01 FIX  
a
Median value and 95% confidence intervals were derived using 1000 re-sampled bootstrap runs 
b
Power term in Equation (5) 

















Figure 10. The basic goodness-of-fit plots of the final 



















Figure 11. Visual predictive check of the final PK model of 
YH4808. Empty circles denote observed concentration; Solid 
lines represent the upper 95th, median, and lower 5th values of 
observed concentrations while dashed lines denote prediction, 
i.e., the upper 95th, median, and lower 5th values of simulated 
concentrations; Shaded areas denote the 95% prediction 
intervals around the simulated upper 95th, median, and lower 5th 
values, respectively, based on the final PK model. 
Concentrations are drawn in the logarithmic scale. 
 
 
Individualized baseline model for intragastric pH 
The baseline pH versus time profiles are adequately described 
by harmonic functions and the circadian pattern is disturbed by 
food intakes that can be observed as peaks in pH values (Figure 
48 
12). In addition, the rises during the later times correspond to 
night hours and can be explained by decreases in hydrogen 















Figure 12. Individual fitting plots of intragastric pH values 
versus time for placebo group (101-114: subject ID number 






The relationship between intragastric pH and plasma 
concentration of YH4808 is well described by the sigmoid 
maximum effect (Emax) model with an effect compartment in 
this study (Figure 13). In addition, to address changes in 
intragastric pH over time affecting the plasma concentration of 
YH4808, we introduced a feedback path such that increased 
intragastric pH decreases the relative bioavailability of YH4808, 
and analyzed PK and PD data simultaneously. An inhibitory 
effect model was used for the feedback by intragastric pH for 
plasma concentrations of YH4808, as follows: 
                          Feedback = 1 −
𝐸𝐷𝑚𝑎𝑥∙𝐼𝑛𝑡𝑟𝑎𝑔𝑎𝑠𝑡𝑟𝑖𝑐 𝑝𝐻
𝐸𝐷50+𝐼𝑛𝑡𝑟𝑎𝑔𝑎𝑠𝑡𝑟𝑖𝑐 𝑝𝐻
             (6) 
,where EDmax is the maximum reduction of the relative 
bioavailability of YH4808 and ED50 is the intragastric pH that 
produces 50% of maximum reduction of the relative 
bioavailability. The IIV of these parameters was evaluated using 
an exponential error model, and the RV was evaluated using an 
additive random effect model. After evaluation of the OFV and 
the model fit, the final PK/PD model was selected including IIV 











Figure 13. Schematic diagram of the final mechanism-based 
pharmacokinetic and pharmacodynamic model of YH4808. 
A sigmoid Emax model with baseline effect was used for linking 
the changes in intragastric pH to the PK model as follows: E0 × 
[(Emax × Ce)/(EC50 + Ce)]. An inhibitory Emax model for the 
feedback was introduced to address changes in intragastric pH 
over time affecting the plasma concentration of YH4808. The 












Table 5. Parameters of the final 





























Additive residual  
variability 
- 1.34 - 
RSE: Relative standard error, CI: confidence interval, CV%: coefficient 
variation expresses as percent 
Emax: maximum effect 
EC50: plasma concentration producing 50% of maximal effect 
ke0: rate constant for elimination from effect compartment 
EDmax: maximal reduction of relative bioavailability 









Figure 14. The basic goodness-of-fit plots of the final 
pharmacokinetic and pharmacodynamic model of YH4808: 




In this study, the PBPK and PK/PD models developed using 
combined bottom-up and top-down approaches (i.e., middle-
out approach) were able to capture mechanistically the inter-
relationship between plasma concentrations of YH4808 and 
intragastric pH profiles over 24 hour period after single and 
multiple administrations of YH4808 in humans. The reduced 
solubility of YH4808 by elevated intragastric pH after oral 
administration was hypothesized as the main cause of the 
decrease in exposure, and this hypothesis was confirmed by 
PBPK modeling and simulation. In addition, the PK/PD model 
adequately described quantitative mutual relationships between 
the exposure to YH4808 and intragastric pH by introducing a 
feedback loop such that increased intragastric pH decreases the 
relative bioavailability of YH4808. As a whole, the potential 
mechanism of YH4808 that the decrease of the relative 
bioavailability was caused by elevated intragastric pH was 
confirmed by the PBPK model, and this mechanism based 
PK/PD model best described the decrease in the systemic 
exposure of YH4808 after multiple oral administration.  
 In PBPK modeling study, the human PK parameters of 
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YH4808 estimated by optimized PBPK model using the ADAM 
module were similar to the observed ones after a single oral 
administration at 50-400 mg (Table 2 and Figure 6). However, 
the human PBPK model failed to predict the decrease in the 
systemic exposure to YH4808 after repeated oral 
administration, particularly at higher doses such as 200 and 400 
mg (Figure 7) although the ratio of the model-predicted PK 
parameter to the observed value fell entirely within the pre-
specified range of 0.5-2.0 (Table 3).  
Several hypotheses can be proposed. First, the low oral 
bioavailability of YH4808 along with its huge interindividual 
variability (mean: 10.1%, range: 2.3-19.3%) might have 
contributed to the reduced exposure to YH4808 after multiple 
administration [14]. This mechanism, however, does not appear 
to fully explain the decrease in the systemic exposure to 
YH4808 after repeated oral administration because the 
decreased exposure was seen rather consistently at all doses 
studied. Second, altered drug metabolism and transporter 
activities for YH4808, particularly after repeated administration, 
could be another possibility. However, YH4808 did not induce 
the CYP450 isozymes in human hepatic microsomes. 
Furthermore, YH4808 has a high permeability (1.49 x 10-5 
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cm/sec) and is not a substrate of efflux transporters based on 
the Caco-2 cell permeability study, suggesting altered drug 
metabolism and transporter activities was less likely [32,33].  
Therefore, we should consider other explanations, 
which are mechanistically more plausible. Changes in 
biopharmaceutical properties such as solubility after repeated 
oral administration with YH4808 can be a candidate. YH4808 
has a pH-dependent solubility; the solubility of YH4808 is 
dramatically decreased as pH is increased, e.g., 2.137 and 
0.046 mg/mL at pH 2.0 and 6.0, respectively (Table 1). 
Repeated oral administration of YH4808 is expected to increase 
intragastric pH similar to that in the small and large intestines 
because acid secretion in the stomach is inhibited. To support 
this notion, the intragastric pH remained high (i.e., pH >4) over 
24 hours after repeated oral administration of YH4808 at 400 
mg once daily [10]. Consequently, an approximately 50-fold 
decrease in solubility of YH4808 after multiple administration 
could have negatively affected the absorption of YH4808.  
Based on the hypothesis, we investigated the effect of 
increased intragastric pH on the exposure to YH4808 using the 
SimCYP®  Simulator. As we varied intragastric pH from 1.5 (i.e., 
normal physiology in the fasting state) to 4 to 7, the PK profiles 
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of orally-administered YH4808 was simulated. In this 
simulation, no assumption was made as to precipitation time 
because slow dissolution of YH4808 in the elevated gastric pH 
is not expected to cause supersaturation in the small intestine 
[24]. As intragastric pH was increased from 1.5 to 7, the Cmax 
and AUC0-t of YH4808 after oral administration at 400 mg were 
reduced by 12.7-28.9% and 7.9-18.6%, respectively (Figure 
8). Therefore, the decrease in the exposure to YH4808 after 
repeated administration (Figure 7(b)-(c)) could have been 
most likely caused by the reduced solubility of YH4808 as the 
intragastric pH was increased. Similarly, elevated gastric pH 
induced by concomitantly-administered ARAs decreased the 
exposure of weak base drugs having pH-dependent solubility.14 
For example, palbociclib, a highly selective inhibitor of cyclin-
dependent kinase 4 and 6, showed a reduced Cmax and AUC0-t 
by 80% and 62%, respectively, when co-administered with 
rabeprazole, an ARA [34].   
 This study had some limitations. First, our simulation 
based on increased intragastric pH, which was chosen rather 
arbitrarily, did not reflect its dynamic changes over time. 
Therefore, the effect of increased intragastric pH on the 
exposure to YH4808 was static at best. Second, the observed 
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decrease in the exposure to YH4808 after repeated 
administration was larger than those simulated with intragastric 
pH being increased from 1 to 7 (56.3% vs. 28.9% for Cmax; 46.3% 
vs. 20.5% for AUC0-t). Therefore, there might be other factors 
than the decreased solubility that could explain the additional 
decrease in the exposure to YH4808 after repeated 
administration. Third, the effect of increased intragastric pH 
was not incorporated in the final human PBPK model. Therefore, 
we could not evaluate if the model’s predictive performance 
was improved when the pH-dependent solubility of YH4808, 
particularly after repeated administration, was adequately 
integrated into the model. A more appropriate PBPK model 
should include the effect of change in intragastric pH by 
YH4808 on its PK. However, this model requires a deeper, 
quantitatively more complex understanding on the PK/PD 
relationship between YH4808 and intragastric pH. Thus, we 
have carried out the PK/PD analysis in the next part of our 
study. Even with all these limitations, however, we believe that 
the pH-dependent solubility of YH4808 was still the main 
mechanism for the reduced exposure after repeated oral 
administration as we showed in a prediction of varying 
intragastric pH (Figure 8). 
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To solve the last limitation of the PBPK modeling and 
simulation as mentioned above, we developed the mechanism-
based PK/PD model of YH4808 using clinical data of phase I 
study. The mechanism such that increased intragastric pH 
decreases the relative bioavailability was confirmed in our 
PBPK modeling and simulation study of YH4808. This 
mechanism was applied to the PK/PD model to mechanistically 
explain the relationship of PK and PD of YH4808. A 
mechanism-based PK/PD model generally contains specific 
expressions for the characterization of processes on the causal 
path between drug exposure and response [35]. In our PK/PD 
model, we assessed inter-relationships between the time 
course of intragastric pH and that of the plasma concentration 
of YH4808. Intragastric pH profiles in a placebo group would be 
helpful to estimate the food effect and circadian rhythm 
robustly because there would be no drug effect in this group. 
The circadian rhythm pattern of intragastric pH is a 
consequence of the circadian rhythm of hydrogen secretion. 
The mechanism of alteration of hydrogen secretion by the 
inactivation of the H+/K+-ATPase enzyme has been modeled 
previously [36]. The baseline effect of intragastric pH in the 
PK/PD model also accounts for the circadian rhythm of 
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hydrogen ion production and the effects of food intake. Plotting 
of individual plasma concentrations of YH4808 with concurrent 
intragastric pH values showed a counterclockwise hysteresis 
loop for each subject. This hysteresis was caused by a delayed 
occurrence of the maximum response relative to the time 
course of YH4808 concentration. The observed delay between 
concentration and response in this study is consistent with 
earlier studies on PK/PD relationships of ARAs [37,38]. The 
hypothetical effect compartment was integrated our PK/PD 
model because it has been commonly applied when 
anticlockwise hysteresis is present in the concentration-effect 
plot.  
In addition, a feedback path was introduced to explain the 
effect of increased intragastric pH on the systemic exposure of 
YH4808 in healthy subjects. In previous studies, an interaction 
between drug responses (i.e., drug effect) and PK 
characteristics of drug was explained using a feedback 
mechanism. For example, the population PK/PD model of 
pegfilgrastim, a PEGylated form of the recombinant human 
granulocyte colony-stimulating factor analog filgrastim to 
stimulate bone marrow to produce more neutrophils, included a 
bidirectional PK/PD system of pegfilgrastim, where 
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pegfilgrastim stimulated the proliferation, maturation, and 
margination of neutrophils and where circulating neutrophils in 
turn increased the elimination of pegfilgrastim [39]. Due to the 
bidirectional nature of the system where PK influences PD and 
PD influences the elimination of pegfilgrastim, the population 
PK/PD model of pegfilgrastim introduced a feedback path. 
Another example of feedback mechanism in PK/PD analysis was 
recombinant human erythropoietin (rHuEPO) [40]. The 
mechanism-based PK/PD model of rHuEPO was developed to 
describe the relationship between rHuEPO concentrations and 
the hematological responses to rHuEPO over time, which, in 
turn, drive a time-dependent change in rHuEPO elimination. In 
other words, the negative feedback from red blood cells 
accounted for the time-dependent rHuEPO clearance decline.  
As in the examples above, a feedback mechanism that PD 
influences PK was only used a PK/PD analysis of biologics in 
previous studies.   
Our study was the first attempt to introduce a feedback 
path such that increased intragastric pH (i.e., PD) decreases 
the relative bioavailability (i.e., PK) of YH4808, a small 
molecule drug. Mechanistically, the superiority of the feedback 
model conforms to the assumed action of intragastric pH on the 
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relative bioavailability of YH4808. The result of the proposed 
feedback path was well captured the decreased exposure at 




In conclusion, first, a human PBPK model adequately 
predicted the concentrations of YH4808 observed in a clinical 
study after single and repeated oral administrations. 
Furthermore, a simulation experiment based on the human 
PBPK model indicated that the pH-dependent solubility of 
YH4808 could have resulted in the reduced exposure after 
multiple administration. PBPK modeling and simulation is a 
useful tool to investigate the impact of the biopharmaceutical 
properties of a compound on its PK profiles during clinical 
development. Second, a mechanism-based PK/PD model 
adequately described quantitative relationships between the 
plasma concentrations of YH4808 and the time course of 
intragastric pH after single and multiple oral administrations in 
humans. Our approach using a feedback mechanism in the 
PK/PD analysis is the first mechanistic modeling of a small 
molecule drug to describe the dynamics of the changes in 
intragastric pH following an ARA with pH-dependent solubility. 
Our analysis provides mechanistic insight into the relationship 
between the exposure to YH4808 and intragastric pH, which 
will allow for devising optimal dosing regimens for YH4808 in 
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1. Individual fitting plots for the final pharmacokinetic model of 
YH4808 (DV: dependent variable, IPRED: individual predicted 
values) 
Single ascending dose groups: ID 1101-1111: 30 mg; ID 1201-1211: 
50 mg; ID 1301-1312: 100 mg; ID 1401-1409: 200 mg; ID 1502-
1513: 400 mg; ID 1604-1610: 600 mg; ID 1701-1713: 800 mg  
Multiple ascending dose groups: ID 2301-2311: 100 mg; ID 2402-
2418: 200 mg; ID 2505-2513: 400 mg 
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2. NONMEM control stream of the final PK model                
$SUBROUTINE ADVAN13 TOL=4 
$MODEL  COMP=(GUT) COMP=(CENTRAL) COMP=(PERIPH) 
$PK  
CL = THETA(1)*EXP(ETA(1))*(WT/70)**THETA(9); 
V2 = THETA(2)*EXP(ETA(2)) 
Q = THETA(3)*EXP(ETA(3)) 
V3 = THETA(4)*EXP(ETA(4)) 
KA = THETA(5)*EXP(ETA(5)) 
ALAG1 = THETA(6)*EXP(ETA(6)) 
S2 = V2 
K20 = CL/V2 
K23 = Q/V2 





CP = A(2)/V2 
DADT(1) = -KA*A(1) 
DADT(2) = -K23*A(2)-K20*A(2)+K32*A(3)+KA*A(1) 
DADT(3) = -K32*A(3)+K23*A(2) 
$ERROR  
IPRED = F 
    W = SQRT(THETA(7)**2*IPRED**2 + THETA(8)**2) 
    Y = IPRED + W*EPS(1) 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
 
$THETA   
 (0,500) ; CL 
 (0,500) ; V2 
 (0,500) ; Q 
 (0,5000) ; V3 
79 
 (0,1) ; KA 
 (0,0.1) ; ALAG1 
 (0,.5) ; Prop.RE (sd) 
 0.01 FIX ; Add.RE (sd) 
 (0,1) ; power term for BW 
 
$OMEGA   
 0.3  ;     IIV CL 
 0.3  ;     IIV V2 
 0.3  ;     IIV Q 
 0.3  ;     IIV V3 
 0.3  ;     IIV KA 
 0.3  ;     IIV ALAG1 
 
$SIGMA  1  FIX  ; Proportional error PK 
$ESTIMATION METHOD=1 INTER MAXEVAL=9999 NOABORT 
SIGL=3 NSIG=1 PRINT=5 POSTHOC 
$COVARIANCE 
$TABLE      ID TIME TAD OCC DV MDV EVID IPRED IWRES 
CWRES ONEHEADER NOPRINT FILE=sdtab150 
$TABLE      CL V2 V3 KA Q K20 K23 K32 ALAG1 FIRSTONLY 







3. Individual fitting plots for the final pharmacokinetic and 
pharmacodynamic model of YH4808 (DV: dependent variable, 
IPRED: individual predicted values) 
Single ascending dose groups: ID 1101-1111: 30 mg; ID 1201-1211: 
50 mg; ID 1301-1312: 100 mg; ID 1401-1409: 200 mg; ID 1502-
1513: 400 mg; ID 1604-1610: 600 mg; ID 1701-1713: 800 mg  
Multiple ascending dose groups: ID 2301-2311: 100 mg; ID 2402-
2418: 200 mg; ID 2505-2513: 400 mg 
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4. NONMEM control stream of the final PK and 
PD model 
$SUBROUTINE ADVAN13 TOL=6 
$MODEL   COMP=(DEPOT) COMP=(CENTRAL) COMP=(PERIPH) 
COMP=(EFFECT) 
$PK    
CL = THETA(1)*EXP(ETA(1))*(WT/70)**THETA(24) 
V2 = THETA(2)*EXP(ETA(2)) 
Q = THETA(3)*EXP(ETA(3)) 
V3 = THETA(4)*EXP(ETA(4)) 
KA = THETA(5)*EXP(ETA(5)) 
ALAG1 = THETA(6)*EXP(ETA(6)) 
 
K20 = CL/V2 
K23 = Q/V2 
K32 = Q/V3 
K12 = KA 
 
IF (CMT .EQ. 2) THEN 
S2 = V2 
 
ELSE 
S2 = 1 
ENDIF 
 
A0 = THETA(7) ;* EXP(ETA(7)) 
A1 = THETA(8) ;* EXP(ETA(8)) 
A2 = THETA(9) ;* EXP(ETA(9)) 
A3 = THETA(10) ;* EXP(ETA(10)) 
A4 = THETA(11) ;* EXP(ETA(11)) 
C1 = THETA(12) ;* EXP(ETA(12)) 
C2 = THETA(13) ;* EXP(ETA(13)) 
C3 = THETA(14) ;* EXP(ETA(14)) 
C4 = THETA(15) ;* EXP(ETA(15)) 
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E0 = A0 + A1*COS(2*3.1416*(TAD-C1)/24) + 
A2*SIN(2*3.1416*(TAD-C2)/18) + A3*COS(2*3.1416*(TAD-
C3)/12) + A4*SIN(2*3.1416*(TAD-C4)/6) 
 
EMAX = THETA(16)*EXP(ETA(7)) 
EC50 = THETA(17)*EXP(ETA(8)) 
KE0 = THETA(18)*EXP(ETA(9)) 
EDMAX = THETA(19)*EXP(ETA(10)) 
ED50 = THETA(20)*EXP(ETA(11)) 
 
$DES   
DCP = A(2)/V2 
DCE = A(4) 
  
DADT(1) = -KA*A(1) 
DADT(2) = -K23*A(2)-K20*A(2)+K32*A(3)+KA*A(1) 
DADT(3) = -K32*A(3)+K23*A(2) 
DADT(4) = KE0*(DCP-DCE) 
 
$ERROR   
CP = A(2)/V2 
CE = A(4) 
Q1 = 1 ; dummy indicator for compartment 2 
 
IF (CMT .EQ. 4) Q1=0 
 
PH = E0*(1+(EMAX*CE)/(EC50+CE)) ; Emax model for pH driven 
by effect compartment concentration 
PHPK = 1-(EDMAX*PH)/(ED50+PH)   ; Inhibitory effect model 
for the feedback by pH for plasma concentration of YH4808 
IPRED = Q1*CP*PHPK + (1-Q1)*PH 
W = Q1*SQRT(THETA(21)**2*IPRED**2 + THETA(22)**2) + 
(1-Q1)*SQRT(THETA(23)**2) 
IRES = DV-IPRED 
IWRES = IRES/W 
Y = IPRED+W*EPS(1) 
 
$THETA  (0,500) ; CL 
 (0,500) ; V2 
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 (0,500) ; Q 
 (0,5000) ; V3 
 (0,1) ; KA 
 (0,0.1) ; ALAG1 
 (0.1,5) ; A0 
 (0.1,1) ; A1 
 (0.001,1) ; A2 
 (-1,0.1) ; A3 
 (-1,0.1) ; A4 
 (0.1,10) ; C1 
 (0.01,1) ; C2 
 (0.01,1) ; C3 
 (0.1,5) ; C4 
 (0,0.1) ; EMAX 
 (0,500) ; EC50 
 (0.01,1) ; KE0 
 (0,0.5) ; EDMAX 
 (0,5) ; ED50 
 (0,0.3) ; Prop RE (sd) 
 0.01 FIX 
 (0,0.5) ; Additive RE 
 (0,1) ; power term of weight 
$OMEGA  0.5  ;       ETA1 
 0.5  ;       ETA2 
 0.5  ;       ETA3 
 0.5  ;       ETA4 
 0.5  ;       ETA5 
 0.5  ;       ETA6 
 0.5  ;       ETA7 
 0.5  ;       ETA8 
 0.5  ;       ETA9 
 0.5  ;      ETA10 
 0.5  ;      ETA11 
$SIGMA  1.0  FIX 
$ESTIMATION METHOD=1 INTER MAXEVAL=9999 NOABORT 
SIGL=6 NSIG=2 PRINT=5 POSTHOC 
$COVARIANCE 
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$TABLE      ID TIME TAD OCC AMT CMT MDV IPRED IWRES 
CWRES ONEHEADER NOPRINT FILE=sdtab1007 
$TABLE      ID CL V2 Q V3 ALAG1 KA E0 EMAX EC50 KE0 













위산 펌프 길항제와 위 내 산도 상호간의 효능 관계를 
규명하기 위한 생리학적 약물 동태 모델과 
약동/약력학 모델 구축 연구 





서론: 위산 분비와 관련된 질환의 치료제로 개발 진행 중인 
YH4808 은 위산 분비를 담당하는 효소인 H+/K+-ATPase 에 
작용하여, 이 효소를 가역적, 선택적으로 불활성화시키는 칼륨 
경쟁적 위산 분비 차단제 (Potassium-Competitive Acid Blocker, 
P-CAB)이다.  임상 1 상 시험 결과, YH4808 30-800 mg 을 
건강한 남성 자원자에게 단회 투여하였을 때, YH4808 의 
약동학(혈중 농도 변화)은 용량 비례적인 양상을 보였다. 그러나, 
YH4808 반복 투여 시(특히, 고용량군 (200, 400 mg)), 전신 
노출이 감소하였다. YH4808 반복 투여 후, 위 내 pH 상승에 의한 
YH4808 의 용해도 감소가 노출 감소의 주요 원인으로 제기되었다. 
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본 연구에서는, 첫째, 단회 및 반복 투여 시 YH4808 의 
약동학(혈중 농도) 프로파일을 예측하기 위한 생리학적 약물 동태 
모델을 구축하였고, 이 모델을 사용하여 고용량 반복 투여 시 
나타나는 YH4808 의 노출 감소를 기전 중심으로 원인을 
규명하였다. 둘째로, YH4808 단회 및 반복 투여 후, YH4808 의 
혈중 농도와 시간에 따른 위 내 pH 변화와의 상호 관계를 
정량적으로 평가하기 위하여 약동/약력학 모델을 구축하였다.  
방법: 생리학적 약물 동태 모델은 YH4808 의 물리화학적 특성, in 
vitro 비임상 데이터, 임상 데이터를 사용하여 개발된 후, 임상 1 상 
단회 투여 데이터를 사용하여 개선되었다. 생리학적 약물 동태 모델 
구축에는 SimCYP (Certara USA, Inc., Princeton, USA) 
시뮬레이터가 사용되었다. 생리학적 약물 동태 모델의 각 구획은 뇌, 
심장, 폐, 신장, 근육, 비장, 간, 위장관, 췌장을 의미하고, 그 외 
나머지 조직들은 하나의 구획으로 만들었다. 위장관과 간을 제외한 
모든 구획은 약물 분포가 매우 신속하게 일어나고, 약물의 청소율은 
혈류에 의해서 제한된다고 가정하였다. YH4808 의 체내 흡수 
양상의 경우, 위장관과 간에서는 permeability-limited 
disposition 을 가정하고, SimCYP 시뮬레이터에 내장되어 있는 the 
advanced dissolution, absorption and metabolism (ADAM) 
모델을 사용하여 예측하였다.  YH4808 은 대부분 담즙으로 
배설되므로, 청소율은 in vitro hepatic microsomal intrinsic 
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clearance data 를 이용하여 계산하였다.  약동/약력학 모델은 
YH4808 의 임상 1 상 시험을 완료한 건강한 자원자 (단회 (30-
800 mg) 또는 반복 (100-400 mg) 투여)의 혈중 농도와 위 내 
pH 데이터 (위약 데이터 포함)를 하나의 데이터셋으로 합쳐 
동시적으로 개발하였다. 약동/약력학 파라미터의 추정은 NONMEM 
(version 7.3., ICON Development Solutions, Ellicott City, MD, 
USA) 프로그램에 내장되어 있는 first-order conditional 
estimation with interaction (FOCE-I) 방법을 사용하였고, 공변량 
(예., 나이, 체중, 키)의 영향 또한 평가하였다. 추정된 파라미터의 
정밀도, diagnostic plot, visual predictive checks plot 결과 등을 
고려하여 최종적으로 가장 적합한 모델을 선정하였다. 
결과: 생리학적 약물 동태 모델 구축 연구 결과, 단회 투여의 경우 
개선된 모델을 사용하여 YH4808 의 혈중 농도 양상이 잘 예측된 
반면, 반복 투여의 경우 200 mg 과 400 mg 용량군에서 나타난 
약물의 노출 감소 현상은 잘 예측하지 못하였다. YH4808 반복 
투여시 고용량 군에서 나타나는 이런 약물의 노출 감소 현상의 
원인을 찾기 위하여 위 내 pH 증가가 YH4808 의 용해도를 
감소시키고, 이런 약물의 물리화학적 특성이 약물 노출을 
감소시킨다고 가정하였다. 이러한 가정은 구축된 생리학적 약물 
동태 모델에서 위 내 pH 를 인위적으로 상승시킴에 따른 
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YH4808 의 체내 노출 변화를 시뮬레이션하여 최종적으로 
검증하였다.  
다음으로, 약동/약력학 모델 구축 연구 결과, 흡수 지연 시간이 
있는 1 차 흡수를 보이는 2 차 구획 약동학 모델과 효과처 구획 
모델이 연결된 S 자 모양 최대 효과 모델 (sigmoid maximum 
effect model)을 사용하여 YH4808 투여 후 관찰된 혈중 농도와 
24 시간 동안의 위 내 pH 프로파일을 잘 예측하였다. 또한, 시간에 
따른 위 내 pH 변화가 다시 YH4808 혈중 농도에 영향을 주는 
현상을 설명하기 위하여, 위 내 pH 상승이 YH4808 의 상대적 
생체이용률을 감소시키는 되먹임 경로를 모델에 추가하였다. 
결론: 본 연구에서, 생리학적 약물 동태 모델은 YH4808 단회 및 
반복 투여 후 YH4808 의 혈중 농도를 잘 예측하였고, 구축된 
모델을 사용하여 YH4808 의 pH 의존 용해도(pH-dependent 
solubility)가 반복투여 시 나타나는 노출 감소 현상의 원인이라는 
것을 증명하였다. 이러한 기전을 YH4808 의 약동/약력학 모델에 
반영하여 단회 및 반복 투여 시 YH4808 의 혈중 농도와 위 내 pH 
변화와의 상호 관계를 정량적으로 잘 설명하였다. 결론적으로, 본 
연구는 YH4808 의 체내 노출과 위 내 pH 변화 간의 관계를 
파악하는데 기전적 통찰력을 제공하였고, 이는 YH4808 의 최적 




주요어: 위 내 pH, 생리학적 약물 동태, 약동학, 약력학, 모델링, 
시뮬레이션, 칼륨 경쟁적 위산 분비 차단제 
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